Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma

PR Newswire October 14, 2015

CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants

PR Newswire September 21, 2015

CASI Pharmaceuticals Reports Second Quarter 2015 Financial Results

PR Newswire August 14, 2015

CASI Pharmaceuticals Appoints Leading Oncology Experts To Newly Formed Clinical Advisory Board

PR Newswire July 27, 2015

CASI Pharmaceuticals Announces Availabilty Of Anti-Cancer Drug ZEVALIN® In Hong Kong For Non-Hodgkin's Lymphoma

PR Newswire July 20, 2015

CASI Pharmaceuticals To Present At The 2015 BIO International Convention

PR Newswire June 11, 2015

CASI Pharmaceuticals, Inc. (Nasdaq:CASI) to Ring the Nasdaq Stock Market Closing Bell

GlobeNewswire June 10, 2015

CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma

PR Newswire June 4, 2015

CASI Pharmaceuticals Reports First Quarter 2015 Financial Results

PR Newswire May 15, 2015

CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma

PR Newswire March 30, 2015

CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results

PR Newswire March 27, 2015

CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China

PR Newswire March 25, 2015

CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer

PR Newswire March 4, 2015

CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference

PR Newswire March 3, 2015

CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC)

PR Newswire February 9, 2015

CASI Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference

PR Newswire February 2, 2015

CASI Pharmaceuticals Highlights 2014 Accomplishments And 2015 Milestones

PR Newswire January 16, 2015

CASI Pharmaceuticals To Hold Business Update Conference Call And Webcast On January 6th

PR Newswire December 23, 2014

CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma

PR Newswire December 17, 2014

CASI Pharmaceuticals Reports Third Quarter 2014 Financial Results

PR Newswire November 14, 2014